Clinical Trials Browser

INDUSTRY × Melanoma × dabrafenib × Clear all

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

Melanoma, Skin Neoplasms

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

Fever, Melanoma

Melanoma, Skin Neoplasms

Melanoma, Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Brain Neoplasms, Melanoma

Melanoma, Neoplasms, Skin Neoplasms

Melanoma, Neoplasms

Melanoma, Neoplasms

Melanoma, Neoplasm Metastasis, Skin Neoplasms

Melanoma, Neoplasms

Brain Neoplasms, Melanoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis

Melanoma, Neoplasms

Brain Neoplasms, Melanoma

Melanoma, Neoplasms

Melanoma, Neoplasms

Clinical Trials

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Dabrafenib and/or Trametinib Rollover Study

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

LEAD Melanoma

COMBI-i

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

COMBI-APlus

Combi-EU

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

COMBI-AD

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

MK-3475-022

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

COMBI-v

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam